Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring
Águeda Molinos-Quintana(Instituto de Biomedicina de Sevilla), Josè Antonio Pérez-Simón(Instituto de Biomedicina de Sevilla), Víctor Galán‐Gómez(Hospital La Paz Institute for Health Research), Berta González‐Martínez(Hospital Universitario La Paz), Antonio Pérez‐Martínez(Hospital Universitario La Paz), Javier Delgado‐Serrano(Instituto de Biomedicina de Sevilla), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Concepción Pérez de Soto(Instituto de Biomedicina de Sevilla), Blanca Herrero(Hospital General Universitario Gregorio Marañón), Anna Alonso‐Saladrigues(Hospital Sant Joan de Déu Barcelona), Anna Faura(Hospital Sant Joan de Déu Barcelona), Montserrat Torrebadell(Hospital Sant Joan de Déu Barcelona), Teresa Caballero‐Velázquez(Instituto de Biomedicina de Sevilla), Melissa Panesso(Vall d'Hebron Institut de Recerca), Ana Castillo‐Robleda(Hospital Infantil Universitario Niño Jesús), José María Pérez‐Hurtado(Hospital Universitario Virgen del Rocío), Susana Rives(Hospital Sant Joan de Déu Barcelona)
Cited by 1
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
|Nature Immunology|2011|724
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442